港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

医药外包概念

2,461.148

+78.8533.31%

涨家数：6

跌家数：2

平家数：- -

市盈率：- -

高：2,534.056

开：2,382.859

低：2,375.883

收：2,382.295

数据加载中...

广生堂(300436.SZ)：乙肝治疗一类创新药奈瑞可韦GST-HG141的III期临床试验首例受试者成功入组

生物股份(600201.SH)子公司获得兽用生物制品临床试验批件

药明康德(02359.HK)7月25日斥资2699.76万元回购30.3万股A股

金斯瑞生物科技07月25日主力净流出2704.4万元散户资金买入

药明生物07月25日获主力加仓1.8亿元

昭衍新药07月25日获主力加仓465.3万元

瑞普生物(300119.SZ)获得兽用生物制品临床试验批件

大和：维持药明生物(02269.HK)“买入”评级盈喜胜预期

港股异动 | 中国抗体-B涨超19%，配股筹资3.69亿港元用于临床试验

港股异动 | 中国抗体-B(03681.HK)再涨超20% 公司配股筹资净筹3.69亿港元拟用于SM03临床试验等项目

大行评级｜高盛：药明生物发盈喜维持对其“中性”评级及目标价25.6港元

大行评级｜大和：维持药明生物“买入”评级上半年盈喜超预期

方达控股盘中异动大幅拉升5.52%

创新药板块迎利好催化？港股昭衍新药、药明生物升超6%

港股异动 | 药明生物涨超6%，公司预计上半年纯利同比增超56%

老虎资讯综合

CRO概念盘中拉升，博腾股份涨6.77%

新股首日 | 维立志博-B(09887.HK)首挂上市早盘高开近107% 核心产品LBL-024为处于注册临床试验阶段的4-1BB靶向候选药物

同源康医药-B(02410.HK)：TY-302、TY-2699a及TY-0540的I期临床试验结果获2025年欧洲肿瘤内科学会(ESMO)大会以壁报形式收录

同源康医药-B(02410)：TY-302、TY-2699a及TY-0540的I期临床试验结果获2025年欧洲肿瘤内科学会(ESMO)大会以壁报形式收录

大行评级｜大摩：药明生物发盈喜予其目标价35港元及“增持”评级

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/BK1576/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1576","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","market":"HK","secType":"PLATE","nameCN":"医药外包概念","latestPrice":2461.148,"timestamp":1753430886160,"preClose":2382.2947,"halted":0,"volume":202568720,"delay":0,"changeRate":0.0331,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":78.853271,"latestTime":"07-25 16:00:00","open":2382.8591,"high":2534.0562,"low":2375.8826,"amount":6024679434.2,"amplitude":0.066395,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753666200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1753407000000,1753416000000],[1753419600000,1753430400000]],"pbRate":2.905027,"peRate":13.881935,"turnoverRate":0.017592,"increases":6,"decrements":2,"flats":0,"marketCap":558178889472,"floatMarketCap":227049556480},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","high":2534.0562,"amplitude":0.066395,"preClose":2382.2947,"low":2375.8826,"pbRate":"2.905027","latestPrice":2461.148,"volume":202568720,"delay":0,"open":2382.8591,"prevYearClose":1395.7731,"prevWeekClose":2262.402,"prevMonthClose":1988.255,"prevQuarterClose":1988.255,"fiveDayClose":2262.402,"twentyDayClose":1938.457,"sixtyDayClose":1672.916,"secType":"PLATE","market":"HK","turnoverRate":0.017592,"peRate":13.881935,"marketCap":558178889472,"floatMarketCap":227049556480,"timestamp":1753430886160,"nameCN":"医药外包概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1576\",,,,undefined,":{"bkCode":"BK1576","up":6,"down":2,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1576\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2554630017","title":"广生堂(300436.SZ)：乙肝治疗一类创新药奈瑞可韦GST-HG141的III期临床试验首例受试者成功入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2554630017","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554630017?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 17:51","pubTimestamp":1753437067,"startTime":"0","endTime":"0","summary":"智通财经APP讯，广生堂 发布公告，公司创新药控股子公司福建广生中霖生物科技有限公司的在研乙肝治疗一类创新药奈瑞可韦GST-HG141的III期临床试验，已于2025年7月25日在树兰(杭州)医院完成首例受试者成功入组给药。2024年11月，GST-HG141的II期临床研究成果被全球肝病研究领域的权威专业学术机构美国肝病研究协会作为最新突破摘要形式接受并展示。2024年12月，GST-HG141被国家药品监督管理局药品审评中心纳入突破性治疗品种名单。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1322045.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","BK1161","III","GST","BK4134","BK0239","03347","300436","BK1574","BK1583","BK1576","BK1141","06978"],"gpt_icon":0},{"id":"2554757652","title":"生物股份(600201.SH)子公司获得兽用生物制品临床试验批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2554757652","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554757652?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 16:32","pubTimestamp":1753432351,"startTime":"0","endTime":"0","summary":"智通财经APP讯，生物股份(600201.SH)发布公告，近日，公司全资子公司金宇保灵生物药品有限公司(简称“金宇保灵”)收到了农业农村部颁发的猫传染性腹膜炎mRNA疫苗临床试验批件(批件号：2025062)。猫传染性腹膜炎mRNA疫苗属于新型创新疫苗，公司率先攻克抗原设计及核酸疫苗产业化难点，成为全国首家获得猫传染性腹膜炎兽用核酸疫苗临床批件的公司，为公司后续兽用核酸疫苗发展奠定基础。兽用疫苗产品从前期研发到上市销售整个周期较长，项目研究开发进度、技术成果、后期产业化应用进程等尚存在一定不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1321966.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0028","600201","BK0185","BK0012","BK0077","BK0239","03347","BK0046","BK0196","BK1583","BK1576","BK1141"],"gpt_icon":0},{"id":"2554576997","title":"药明康德(02359.HK)7月25日斥资2699.76万元回购30.3万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2554576997","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554576997?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 16:32","pubTimestamp":1753432335,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0320764599.SGD","LU0456842615.SGD","603259","BK1583","BK1141","LU0052750758.USD","LU2045819591.USD","LU1046422090.SGD","159982","LU2488822045.USD","399300","LU2328871848.SGD","LU1997244956.HKD","LU0708995583.HKD","LU2242644610.SGD","LU1997245177.USD","BK1576","LU2495084118.USD","LU1969619763.USD","LU1997245094.SGD","LU2125910500.SGD","BK0216","02359"],"gpt_icon":0},{"id":"2554576244","title":"金斯瑞生物科技07月25日主力净流出2704.4万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2554576244","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554576244?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 16:16","pubTimestamp":1753431365,"startTime":"0","endTime":"0","summary":"07月25日, 金斯瑞生物科技股价跌2.62%，报收17.84元，成交金额5.2亿元，换手率1.31%，振幅4.91%，量比0.78。金斯瑞生物科技今日主力资金净流出2704.4万元，上一交易日主力净流入313.0万元。该股近5个交易日上涨5.95%，主力资金累计净流入2112.7万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入8790.8万元，其中净流入天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725170127a462ffc1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725170127a462ffc1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000306685.HKD","HK0000320264.USD","HK0000306701.USD","BK1583","01548","BK1576","BK1141","HK0000320223.HKD"],"gpt_icon":0},{"id":"2554764335","title":"药明生物07月25日获主力加仓1.8亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2554764335","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554764335?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 16:15","pubTimestamp":1753431359,"startTime":"0","endTime":"0","summary":"07月25日, 药明生物股价涨5.53%，报收31.50元，成交金额28.3亿元，换手率2.21%，振幅8.71%，量比1.46。药明生物今日主力资金净流入1.8亿元，连续3日净流入，上一交易日主力净流入2.4亿元。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为56.25%，平均涨幅为4.30%。该股近5个交易日上涨10.33%，主力资金累计净流入5.9亿元；近20日主力资金累计净流入8.9亿元，其中净流入天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725165918a462fe89&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725165918a462fe89&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359202008.SGD","LU0052750758.USD","LU0516422366.SGD","LU0181495838.USD","LU0417516738.SGD","LU0516422952.EUR","LU1720050803.USD","LU0039217434.USD","LU2039709279.SGD","LU0572944931.SGD","LU0043850808.USD","LU0359201612.USD","LU0140636845.USD","LU0819121731.USD","LU0327786744.USD","LU0516422440.USD","LU0320764599.SGD","02269","LU0588546209.SGD","IE00B0JY6N72.USD","SG9999002463.SGD","LU0051755006.USD","LU0456827905.SGD","BK1576","LU1242518857.USD","BK1589","LU0348735423.USD","LU0823426308.USD","LU1880383366.USD","SG9999002562.SGD","LU0516423174.USD","LU0307460666.USD","LU0348825331.USD","LU0326950275.SGD","LU0979878070.USD","LU0417516902.SGD","BK1610","BK1141","LU0823426480.USD","LU0708995583.HKD","LU0456846285.SGD","LU1794554557.SGD","LU0516423091.SGD","BK1521","LU0856984785.SGD","LU1242518931.SGD","LU1688375341.USD"],"gpt_icon":0},{"id":"2554652377","title":"昭衍新药07月25日获主力加仓465.3万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2554652377","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554652377?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 16:15","pubTimestamp":1753431336,"startTime":"0","endTime":"0","summary":"07月25日, 昭衍新药股价涨7.02%，报收24.40元，成交金额2.0亿元，换手率7.04%，振幅9.43%，量比1.33。昭衍新药今日主力资金净流入465.3万元，连续3日净流入，上一交易日主力净流入949.7万元。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为66.67%，平均涨幅为3.09%。该股近5个交易日上涨11.67%，主力资金累计净流入2834.4万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入4747.7万元，其中净流入天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725165048a462fa10&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725165048a462fa10&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06127","BK1576","BK1141"],"gpt_icon":0},{"id":"2554542977","title":"瑞普生物(300119.SZ)获得兽用生物制品临床试验批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2554542977","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554542977?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 15:48","pubTimestamp":1753429739,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞普生物(300119.SZ)发布公告，近日，公司收到了农业农村部颁发的猪流行性腹泻病毒mRNA疫苗(RPS1903)临床试验批件(批件号：2025061)。此次获得的临床批件，是国内首个经济动物用mRNA疫苗临床批件。mRNA疫苗通过精准编码猪流行性腹泻病毒的关键抗原序列，进入机体后直接引导细胞合成抗原蛋白，从而激发强效免疫反应。与传统疫苗相比，mRNA疫苗在研发效率、免疫效果及生物安全风险防控等方面，具备明显优势。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1321944.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0070","300119","BK0239","03347","BK0046","BK1583","BK1576","BK1141"],"gpt_icon":0},{"id":"2554875141","title":"大和：维持药明生物(02269.HK)“买入”评级 盈喜胜预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2554875141","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554875141?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 15:13","pubTimestamp":1753427633,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1589","LU0516422952.EUR","LU0052750758.USD","LU0320764599.SGD","LU1242518857.USD","LU0359202008.SGD","SG9999002562.SGD","LU1720050803.USD","LU0039217434.USD","LU0456846285.SGD","LU0326950275.SGD","LU0417516902.SGD","LU0819121731.USD","SG9999002463.SGD","LU0359201612.USD","LU0181495838.USD","LU0516423174.USD","LU0708995583.HKD","IE00B0JY6N72.USD","LU0348735423.USD","LU0572944931.SGD","LU0516423091.SGD","LU1794554557.SGD","02269","BK1576","LU0979878070.USD","LU0588546209.SGD","LU0140636845.USD","LU0043850808.USD","LU1880383366.USD","LU0348825331.USD","LU0417516738.SGD","BK1610","LU1688375341.USD","LU0327786744.USD","LU0516422366.SGD","BK1521","LU2039709279.SGD","LU0051755006.USD","BK1141","LU0823426480.USD","BK4080","ADC","LU0456827905.SGD","LU0823426308.USD","LU0856984785.SGD","LU1242518931.SGD","LU0516422440.USD","LU0307460666.USD","BK4231"],"gpt_icon":0},{"id":"1107966336","title":"港股异动 | 中国抗体-B涨超19%，配股筹资3.69亿港元用于临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1107966336","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107966336?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 11:34","pubTimestamp":1753414492,"startTime":"0","endTime":"0","summary":"7月25日，中国抗体-B盘中涨超19%，公司配股筹资净筹3.69亿港元，拟用于SM03临床试验等项目。消息面上，中国抗体公告，拟发行1.82亿股新股份，认购价为每股2.03港元。该决定乃经内部评估后作出，该评估确定需要补充早期疗效的证据以支持BLA的审批。公司对舒西利单抗获批准于中国上市仍具信心，已开始规划舒西利单抗用于治疗系统性红斑狼疮的新临床开发计划。","market":"us","thumbnail":"https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/content/detail/1321863.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1583","BK1141","03681","BK1161","BK1574","BK1576","BK4614"],"gpt_icon":0},{"id":"2554675834","title":"港股异动 | 中国抗体-B(03681.HK)再涨超20% 公司配股筹资净筹3.69亿港元 拟用于SM03临床试验等项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2554675834","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554675834?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 11:25","pubTimestamp":1753413958,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","BK1161","BK1141","BK1574","03681","BK1576","03347"],"gpt_icon":0},{"id":"2554972730","title":"大行评级｜高盛：药明生物发盈喜 维持对其“中性”评级及目标价25.6港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2554972730","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554972730?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 11:05","pubTimestamp":1753412719,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2039709279.SGD","LU0516422366.SGD","LU2237443382.USD","BK1610","BK1521","LU0819121731.USD","BK4585","LU1688375341.USD","LU2237443978.SGD","SG9999002562.SGD","LU2237443465.HKD","LU0326950275.SGD","LU1242518857.USD","BK4080","LU0588546209.SGD","LU2471134523.USD","02269","LU0823426308.USD","LU0039217434.USD","LU0181495838.USD","LU0516423091.SGD","LU0417516738.SGD","LU0307460666.USD","LU0359201612.USD","LU2750360997.AUD","LU0979878070.USD","ADC","SG9999002463.SGD","IE0002270589.USD","LU1880383366.USD","LU1868836591.USD","LU0106831901.USD","LU1894683348.USD","BK4552","LU0251142724.SGD","LU0043850808.USD","LU0048573561.USD","BK1576","LU2750360641.GBP","LU1668664300.SGD","LU2471134952.CNY","BK4127","LU2237443622.USD","LU1242518931.SGD","LU0140636845.USD","LU0823426480.USD","LU1868837300.USD","LU0327786744.USD","LU0061475181.USD","BK4516"],"gpt_icon":0},{"id":"2554370277","title":"大行评级｜大和：维持药明生物“买入”评级 上半年盈喜超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2554370277","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554370277?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 10:49","pubTimestamp":1753411799,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0516422440.USD","BK1589","LU0572944931.SGD","LU1688375341.USD","BK4080","LU0039217434.USD","LU0327786744.USD","LU0456827905.SGD","02269","LU0417516902.SGD","LU0516422366.SGD","LU0043850808.USD","LU0588546209.SGD","LU0819121731.USD","BK4231","LU0516423091.SGD","LU0979878070.USD","LU0348735423.USD","LU0417516738.SGD","LU0516423174.USD","BK1576","LU2039709279.SGD","LU0823426480.USD","BK1521","SG9999002562.SGD","BK1141","LU0307460666.USD","LU0140636845.USD","LU0348825331.USD","LU0708995583.HKD","LU1794554557.SGD","LU0359201612.USD","LU1242518857.USD","LU0320764599.SGD","SG9999002463.SGD","LU0516422952.EUR","LU0856984785.SGD","IE00B0JY6N72.USD","BK1610","LU0823426308.USD","LU0359202008.SGD","LU0456846285.SGD","LU0181495838.USD","ADC","LU0051755006.USD","LU0326950275.SGD","LU1720050803.USD","LU1880383366.USD","LU1242518931.SGD","LU0052750758.USD"],"gpt_icon":0},{"id":"2554656737","title":"方达控股盘中异动 大幅拉升5.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2554656737","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554656737?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 10:08","pubTimestamp":1753409314,"startTime":"0","endTime":"0","summary":"2025年07月25日早盘10时08分，方达控股股票出现波动，股价快速拉升5.52%。截至发稿，该股报1.720港元/股，成交量24.6万股，换手率0.01%，振幅5.52%。资金方面，该股资金流入7.978万港元，流出33.548万港元。方达控股股票所在的生物技术行业中，整体涨幅为1.10%。其相关个股中，维立志博-B、中国抗体-B、北海康成-B涨幅较大，振幅较大的相关个股有维立志博-B、奥星生命科技、中国抗体-B，振幅分别为21.00%、17.78%、12.17%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725100834a6c0a006&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725100834a6c0a006&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","01521","BK1141","BK1576"],"gpt_icon":0},{"id":"2554373083","title":"创新药板块迎利好催化？港股昭衍新药、药明生物升超6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2554373083","media":"英为财情","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554373083?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 10:08","pubTimestamp":1753409280,"startTime":"0","endTime":"0","summary":"英为财情Investing.com -周五，7月25日，港股三大指数小幅调整，医药板块逆势上升，昭衍新药 、药明生物 升超6%，复星医药 升超4%，药明康德 升超3%。消息面上，近日，国家医保局召开医保支持创新药械系列座谈会第二场。据不完全统计，今年上半年，中国药企对MNC的海外授权交易就超过70笔，据部分已披露的数据，其首付款总额达近30亿美元，交易总额达531.36亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://cn.investing.com/news/stock-market-news/article-2902423","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investing_news","symbols":["LU0359202008.SGD","LU0052750758.USD","LU0516422366.SGD","BK1161","YANG","06127","LU0417516738.SGD","LU0516422952.EUR","603127","LU0039217434.USD","LU2039709279.SGD","LU0572944931.SGD","LU0043850808.USD","06978","LU0359201612.USD","BK4614","LU0140636845.USD","LU0819121731.USD","LU0320764599.SGD","02269","IE00B0JY6N72.USD","LU0456827905.SGD","BK1576","HSTECH","LU1242518857.USD","BK1589","LU0348735423.USD","BK0216","HSCEI","LU0823426308.USD","LU1880383366.USD","SG9999002562.SGD","LU0516423174.USD","LU0307460666.USD","LU0348825331.USD","LU0326950275.SGD","LU0979878070.USD","LU0417516902.SGD","BK1610","BK1141","LU0823426480.USD","LU0708995583.HKD","159992","LU1794554557.SGD","LU0516423091.SGD","BK1521","LU0856984785.SGD","LU1242518931.SGD","LU1688375341.USD"],"gpt_icon":1},{"id":"1174108004","title":"港股异动 | 药明生物涨超6%，公司预计上半年纯利同比增超56%","url":"https://stock-news.laohu8.com/highlight/detail?id=1174108004","media":"老虎资讯综合","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174108004?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 09:58","pubTimestamp":1753408697,"startTime":"0","endTime":"0","summary":"7月25日，$药明生物$盘初涨超6%，公司预计上半年纯利同比增超56%。消息面上，药明$生物$发布业绩预告，预计上半年收益将增长约16%；利润及归属于公司权益股东的利润同比分别增长约54%和56%。$摩根士丹利$发布研报称，药明生物上半年表现较预期好，由毛利率按年扩张3.6个百分点推动。该行认为毛利率扩张主要归因于服务项目增加及利用率提升。","market":"us","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1794554557.SGD","LU0516422440.USD","LU1242518857.USD","LU0320764599.SGD","LU0516422952.EUR","LU0516423174.USD","BK1576","LU2039709279.SGD","IE00B0JY6N72.USD","LU0039217434.USD","LU0327786744.USD","BK1610","02269","LU0708995583.HKD","BK1141","BK4614","LU0348825331.USD"],"gpt_icon":0},{"id":"2554328827","title":"CRO概念盘中拉升，博腾股份涨6.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2554328827","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554328827?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 09:41","pubTimestamp":1753407714,"startTime":"0","endTime":"0","summary":"07月25日，CRO概念盘中拉升，截至09点41分，CRO概念整体指数上涨1.08%，报565.830点。从个股上来看，该概念的成分股中，博腾股份涨6.77%，亚太药业涨幅超过5%。从资金上来看，截止发稿，CRO概念主力净流入为1.41亿，其中药明康德受到资金热捧，主力净流入5759.26万；拉长时间线来看，该板块近20日主力资金净流入-7.23亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072509415494b96ba0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072509415494b96ba0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","BK1576","02359","LU2125910500.SGD","LU1046422090.SGD","LU0320764599.SGD","LU2045819591.USD","BK1583","LU0052750758.USD","LU2242644610.SGD","LU0708995583.HKD"],"gpt_icon":0},{"id":"2554773464","title":"新股首日 | 维立志博-B(09887.HK)首挂上市 早盘高开近107% 核心产品LBL-024为处于注册临床试验阶段的4-1BB靶向候选药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2554773464","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554773464?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 09:24","pubTimestamp":1753406693,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1576","BK1141","BK1583","09887","03347"],"gpt_icon":0},{"id":"2553789679","title":"同源康医药-B(02410.HK)：TY-302、TY-2699a及TY-0540的I期临床试验结果获2025年欧洲肿瘤内科学会(ESMO)大会以壁报形式收录","url":"https://stock-news.laohu8.com/highlight/detail?id=2553789679","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553789679?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 22:51","pubTimestamp":1753368686,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","BK1576","TY","BK1141","159938","BK1161","BK1574","02410","09939","BK1515","03347"],"gpt_icon":0},{"id":"2553678967","title":"同源康医药-B(02410)：TY-302、TY-2699a及TY-0540的I期临床试验结果获2025年欧洲肿瘤内科学会(ESMO)大会以壁报形式收录","url":"https://stock-news.laohu8.com/highlight/detail?id=2553678967","media":"智通财经","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553678967?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 22:51","pubTimestamp":1753368686,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同源康医药-B 发布公告，公司自主研发的三款临床产品TY-302、 TY-2699a及TY-0540的I期临床试验结果，正式获2025年欧洲肿瘤内科学会 大会以壁报形式收录。初步临床数据显示，TY-2699a在同类剂量水平下兼具优异安全性和初步疗效。TY-0540是一种选择性CDK2抑制剂，拟用于治疗乳腺癌、卵巢癌及前列腺癌等其他实体瘤。欧洲肿瘤内科学会成立于1975年，是全球领先的肿瘤学专业学术组织。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1321744.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","BK1576","BK1583","BK1161","BK1574","03347","09939","02410","TY","159938","BK1515"],"gpt_icon":0},{"id":"2553005203","title":"大行评级｜大摩：药明生物发盈喜 予其目标价35港元及“增持”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2553005203","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553005203?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 17:31","pubTimestamp":1753349479,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1880383366.USD","LU0819121731.USD","LU0417516902.SGD","LU0348825331.USD","LU0307460666.USD","LU0359202008.SGD","LU0516422440.USD","LU0039217434.USD","LU0052750758.USD","LU0516423091.SGD","LU1688375341.USD","BK1141","LU1794554557.SGD","LU0516422952.EUR","BK1576","LU0043850808.USD","LU0823426480.USD","LU0856984785.SGD","LU0708995583.HKD","LU0516422366.SGD","SG9999002562.SGD","LU0051755006.USD","LU0320764599.SGD","LU0417516738.SGD","LU0140636845.USD","LU0326950275.SGD","BK1521","02269","LU0456827905.SGD","LU0456846285.SGD","LU2039709279.SGD","LU0348735423.USD","IE00B0JY6N72.USD","LU0181495838.USD","LU0516423174.USD","LU1720050803.USD","BK1589","SG9999002463.SGD","BK1610","LU0327786744.USD","LU0823426308.USD","LU0572944931.SGD","LU1242518931.SGD","LU0588546209.SGD","LU0359201612.USD","LU0979878070.USD","LU1242518857.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":188,"code":"91000000","status":"200"}]}}